Anti-inflammatory agent 117
Anti-inflammatory agent 117 is an orally active anti-inflammatory agent and c-Kit kinase inhibitor with an IC50 of 15.2 μM. Anti-inflammatory agent 117 blocks the NF-κB signaling pathway and inhibits the release of IL-6. Anti-inflammatory agent 117 exhibits anti-inflammatory effects in mouse models of acute lung injury, sepsis and ulcerative colitis. Anti-inflammatory agent 117 can be used in research related to acute lung injury, sepsis and ulcerative colitis.
For research use only. We do not sell to patients.
- Formula: C30H25N5O4S
- Molecular Weight:551.62
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
IL-6 |
In Vitro
Anti-inflammatory agent 117 (Compound z18) (10 μM; 30 min pretreatment followed by 24 h LPS stimulation) potently inhibits LPS-induced IL-6 release in J774A.1 macrophages, with an inhibition rate of 78.55% at the concentration of 10 μM[1].
Anti-inflammatory agent 117 (10 μM; 24 h) exhibits low cytotoxicity in J774A.1 macrophages[1].
Anti-inflammatory agent 117 (10 μM; 2 h) inhibits the activation of the NF-κB signaling pathway in LPS-stimulated J774A.1 macrophages by maintaining IκBα levels and reducing p-p65 levels[1].
Anti-inflammatory agent 117 (10-100000 nM) moderately inhibits c-Kit kinase activity in cell-free biochemical assays, with an IC50 of 15.2 μM[1].
Anti-inflammatory agent 117 (treated at 37°C for 2-8 h) exhibits good 8-hour stability in rat serum, simulated gastric fluid and enzyme-free simulated intestinal fluid at 37°C, and only undergoes moderate degradation in enzyme-containing simulated intestinal fluid (with a residual concentration of approximately 55% after 8 h)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Anti-inflammatory agent 117 (20 mg/kg; p.o.) improves survival outcomes and reduces weight loss in mice with LPS-induced sepsis[1].
Anti-inflammatory agent 117 (20 mg/kg; p.o.; daily; 10 days) significantly ameliorates DSS-induced ulcerative colitis in mice by reducing weight loss, colon shortening, splenomegaly, systemic inflammation, and histopathological tissue damage[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 19-23 g, intratracheal LPS-induced acute lung injury)[1]
-
Dosage:20 mg/kg
-
Administration:p.o.; single dose 30 minutes prior to LPS challenge
-
Result:Significantly reduced the lung wet/dry ratio compared to the LPS group.
Significantly decreased total protein concentration and total cell count in BALF compared to the LPS group.
Significantly reduced BALF levels of IL-6 and TNF-α compared to the LPS group.
Significantly reduced serum levels of IL-6 and TNF-α compared to the LPS group.
Reduced lung tissue neutrophil and macrophage infiltration, attenuated pulmonary edema, congestion, and alveolar wall thickening.
Significantly lowered lung tissue mRNA levels of IL-6, TNF-α, and IL-1β compared to the LPS group.
-
Animal Model:C57BL/6 (intraperitoneal LPS-induced sepsis)[1]
-
Dosage:20 mg/kg
-
Administration:p.o.; single dose 1 hour prior to LPS challenge
-
Result:Delayed mortality (deaths occurring between 36 and 60 hours) with a subset surviving until the end of the 10-day observation period, while all mice in the LPS group died between 24 and 36 hours.
Slowed the rate of weight loss in septic mice, with body weight stabilizing after 60 hours.
-
Animal Model:C57BL/6 (2.5% DSS-induced ulcerative colitis)[1]
-
Dosage:20 mg/kg
-
Administration:p.o.; daily; 10 days
-
Result:Reduced DSS-induced body weight loss, partially restoring weight after DSS withdrawal.
Increased colon length to 7.6 cm (compared to 5.8 cm in the DSS model group).
Reduced spleen weight to near normal control levels.
Maintained a significantly lower DAI score throughout the experimental period compared to the DSS model group.
Significantly reduced serum IL-6 levels compared to the DSS model group.
Attenuated histopathological damage in colon (reduced goblet cell loss, crypt necrosis, and mucosal destruction) and spleen (reduced white pulp fusion and red pulp macrophage infiltration), as well as suppressed inflammatory cell infiltration in colon tissue.
Chemical Information
-
Molecular Weight 551.62
-
Formula C30H25N5O4S
-
SMILES
O=C(C(C(NC1=CC(C)=C(OC2=CC=NC(C(NCCC3=CC=CS3)=O)=C2)C=C1)=O)=N4)C=CN4C5=CC=CC=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
Purity & Documentation
References
[1]. Zhang K, et al. Design, synthesis and anti-inflammatory activity on N-(4-(pyridin-4-yloxy)phenyl)-1,4-dihydropyridazine-3-carboxamide derivative z18 for acute lung injury, sepsis and ulcerative colitis models in mice. European journal of medicinal chemistry. 2026 Jun 06;316:119039. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)